We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Target for Colon Cancer Treatment

By Biotechdaily staff writers
Posted on 25 Oct 2006
Researchers have discovered a new target for potential uses in future colon cancer treatments--a molecule that is implicated in 85% of colon cancer cases.

The study, performed by researchers from the University of Utah's Huntsman Cancer Institute (Salt Lake City, UT, USA), was published online October 6, 2006, in the Journal of Biological Chemistry. More...
By knocking out (genetically disabling) a molecule called C-terminal binding protein (CTBP), researchers were able to save zebrafish from the effects of a mutation in the adenomatous polyposis coli (APC) gene.

In humans, mutations in this gene have long been known to trigger a series of events that cause colon polyps, which ultimately become cancerous. APC mutations play a role in 85% of colon cancers. The new findings mean CTBP also is involved in that percentage of colon cancers.

In zebrafish, APC mutations keep the intestine from developing correctly. "In essence, knocking out CTPB promotes normal development of the intestine in zebrafish carrying an APC mutation,” stated Dr. David A. Jones, a University of Utah associate professor of oncological sciences and leader of the study.

In normal cells of both humans and zebrafish, the APC gene controls the amount of CTBP present by tagging it for destruction. In tumor cells with mutated APC, CTPB is not destroyed; instead it accumulates in the cell. One function of CTBP is to inactivate the process that converts vitamin A into retinoic acid in the cell. Retinoic acid is essential in cell differentiation--the function that determines what type of cell forms and how long it lives.

This study noted that in both zebrafish and human tissues with APC mutations, there are high CTBP levels and a low capability to produce retinoic acid. In APC-mutated tissues in which CTBP had been knocked out, retinoic acid production was restored. Earlier studies in Dr. Jones' lab demonstrated that the lack of retinoic acid caused zebrafish intestines to form incorrectly, and that adding retinoic acid corrected the problems.

"Knocking out CTBP does exactly the same thing, and the logical conclusion is that it's because CTBP controls retinoic acid production,” remarked Dr. Jones. "Since CTBP is a completely new target, we must now look for potential chemical agents that would work to block its actions. That could take three to five years.”



Related Links:
Huntsman Cancer Institute

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

New Insights Into Fetal DNA Could Improve Non-Invasive Prenatal Testing

Non-invasive prenatal testing is widely used to screen pregnancies for genetic conditions by analyzing DNA fragments in maternal blood. Although it offers a safer alternative to invasive procedures such... Read more

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.